This cross-over study investigated children wearing highly aspherical lenslet (HAL) spectacle lenses versus single vision spectacles over three six-month periods. The HAL lenses showed consistent myopia control efficacy and no rebound effect when discontinued over one of the six-month periods.
Estimates on the lifetime cost of myopia management options have shown that although the financial cost is higher in childhood, the cost of staying with traditional non-treatment single vision options is higher over a lifetime.
This study reports two year results from a randomized clinical trial examining myopia control spectacle lenses with highly aspherical lenslets (HAL) or slightly aspherical lenslets (SAL). The findings showed the HAL lens controlled refractive and axial progression by 50-55% and SAL by around 30% over two years. Read more about the outcomes and comparisons to other myopia control spectacles here.
This systematic review of 9 studies confirms that under-correction of myopia does not slow progression; rather, at least half of the studies have shown the myopia progression is accelerated. There was no benefit found in overcorrection, and the evidence for un-correction was equivocal. Clinically, this advocates for the full correction of myopia.
When looking through the ‘treatment zones’ of three different types of myopia controlling spectacle lenses with lenslets, visual acuity is reduced by 3-5 letters and mid-to-high frequency contrast sensitivity is mildly affected compared to single vision spectacles. We’re yet to learn if small differences between designs may influence patient preference.
Children who had already participated in the two-year clinical trial either continued wearing DIMS or switched from the control SV to DIMS. Comparison to an age-matched historical control group showed a myopia control effect in the third year.
This study reports two year results from a randomized clinical trial examining Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for myopia control. The findings showed around 50% refractive and 60% axial length efficacy in Hong Kong Chinese children, with an absolute effect of 0.44D lower refraction and 0.34mm less axial elongation in DIMS wearers.
This study reports one year results from an ongoing randomized clinical trial examining spectacle lenses with highly aspherical lenslet (HAL) or slightly aspherical lenslet (SAL) technology. The findings showed the HAL lens controlled refractive and axial progression by 60-70% and SAL by 30-40% over the first 12 months.
International Myopia Conference (IMC2019). This update includes the IMI new paper, accomodation microfluctuations and DIMS lens.
The session topics covered prevalence, progression and risk factors of myopia, mechanisms such as light exposure and visual pathways, optical and pharmacological methods of myopia control, genetics, clinical trial considerations, myopic eye shape and accommodation and binocularity.
